![Christoph S. Lengauer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christoph S. Lengauer
Fondatore presso Thrive Earlier Detection Corp.
Profilo
Christoph S.
Lengauer is the founder of Thrive Earlier Detection Corp.
(founded in 2019) where he holds the title of Chief Innovation Officer & Director, and Celsius Therapeutics, Inc. (founded in 2018) where he holds the title of Director.
He is currently working as a Director at Presage Biosciences, Inc. since 2015, as well as at MOMA Therapeutics, Inc. and IDRx, Inc. He has previously worked as an Executive Director & Senior Unit Head-Oncology at Novartis Institutes for Biomedical Research, Inc. from 2005 to 2008, as an Independent Director at Relay Therapeutics, Inc., as an Independent Non-Executive Director at HOOKIPA Pharma, Inc. from 2018 to 2022, as a Coaching Director at Baltimore Bays Soccer Club, and as an Associate Professor-Oncology at The Sidney Kimmel Comprehensive Cancer Center from 1997 to 2005.
He has also served as a Venture Partner at Third Rock Ventures LLC from 2016 to 2018, as a Vice President at Sanofi SA from 2008 to 2012, and as the Chief Scientific Officer & Chief Drug Hunter at Blueprint Medicines Corp.
from 2012 to 2016.
Dr. Lengauer has an MBA from The Johns Hopkins University, a graduate degree from Universität Salzburg, and a doctorate degree from Ruprecht-Karls-Universität Heidelberg.
Posizioni attive di Christoph S. Lengauer
Società | Posizione | Inizio |
---|---|---|
Presage Biosciences, Inc.
![]() Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Direttore/Membro del Consiglio | 24/11/2015 |
Celsius Therapeutics, Inc.
![]() Celsius Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Fondatore | 01/04/2018 |
Thrive Earlier Detection Corp.
![]() Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Fondatore | 01/01/2019 |
MOMA Therapeutics, Inc.
![]() MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - |
IDRx, Inc.
![]() IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Christoph S. Lengauer
Società | Posizione | Fine |
---|---|---|
HOOKIPA PHARMA INC. | Direttore/Membro del Consiglio | 30/06/2022 |
BLUEPRINT MEDICINES CORPORATION | Direttore Tecnico/Scientifico/R&S | 21/11/2016 |
Sanofi SA | Corporate Officer/Principal | 01/01/2012 |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | 01/05/2008 |
░░░ ░░░░░░ ░░░░░░ ░░░░░░░░░░░░░ ░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Christoph S. Lengauer
The Johns Hopkins University | Masters Business Admin |
Universität Salzburg | Graduate Degree |
Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
BLUEPRINT MEDICINES CORPORATION | Health Technology |
RELAY THERAPEUTICS, INC. | Health Technology |
HOOKIPA PHARMA INC. | Health Technology |
Aziende private | 10 |
---|---|
Presage Biosciences, Inc.
![]() Presage Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Presage Biosciences, Inc. engages in development of novel drugs for treatment of cancers. It offers CIVO arrayed microinjection platform that allows for simultaneous assessment of multiple drugs or drug combinations directly in a single solid tumor while still in a patient’s body to assess efficacy, resistance, and drug synergies in the tumor’s native microenvironment. The company was founded by James M. Olson and Thane Kreiner in 2008 and is headquartered in Seattle, WA. | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
The Sidney Kimmel Comprehensive Cancer Center
![]() The Sidney Kimmel Comprehensive Cancer Center Hospital/Nursing ManagementHealth Services The Sidney Kimmel Comprehensive Cancer Center offers immune-based treatments for cancer. The company was founded by Sidney Kimmel in 1973 and is headquartered in Baltimore, MD. | Health Services |
Sanofi SA | Health Technology |
Celsius Therapeutics, Inc.
![]() Celsius Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Commercial Services |
Thrive Earlier Detection Corp.
![]() Thrive Earlier Detection Corp. Medical SpecialtiesHealth Technology Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA. | Health Technology |
MOMA Therapeutics, Inc.
![]() MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Health Technology |
Baltimore Bays Soccer Club | |
IDRx, Inc.
![]() IDRx, Inc. Miscellaneous Commercial ServicesCommercial Services IDRx, Inc. is a clinical-stage biopharmaceutical company located in an undisclosed location. The American company is dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today's precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. The company's pipeline programs include small molecule tyrosine kinase inhibitors, and idrx-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRx was founded in 2021 by Alexis A. Borisy, Nicholas B. Lydon, Ben Auspitz, George D. Demetri, and Robert M. Forrester. Ben Auspitz has been the CEO since incorporation. | Commercial Services |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
- Borsa valori
- Insiders
- Christoph S. Lengauer